These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 17724835)

  • 1. Pioglitazone + metformin: new drug. A combination product to avoid.
    Prescrire Int; 2007 Aug; 16(90):144. PubMed ID: 17724835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone/metformin (Actoplus met).
    Med Lett Drugs Ther; 2006 Jan; 48(1227):9-11. PubMed ID: 16444136
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vildagliptin and vildagliptin/metformin: new drug. Same limited efficacy as sitagliptin in type 2 diabetes.
    Prescrire Int; 2008 Oct; 17(97):188. PubMed ID: 19534040
    [No Abstract]   [Full Text] [Related]  

  • 5. Pioglitazone: new indication. No glitazones, with or without insulin, for diabetic patients!
    Prescrire Int; 2008 Oct; 17(97):189. PubMed ID: 19534041
    [No Abstract]   [Full Text] [Related]  

  • 6. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
    Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke].
    MMW Fortschr Med; 2007 Aug; 149(31-32):52-3. PubMed ID: 17849787
    [No Abstract]   [Full Text] [Related]  

  • 8. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone and metformin.
    Hill NR; Matthews DR
    Drugs Today (Barc); 2007 Jul; 43(7):443-54. PubMed ID: 17728845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosiglitazone + glimepiride: new drug. Another combination product to avoid.
    Prescrire Int; 2007 Aug; 16(90):144. PubMed ID: 17726795
    [No Abstract]   [Full Text] [Related]  

  • 11. Pioglitazone + glimepiride: a combination product to avoid.
    Prescrire Int; 2007 Aug; 16(90):145. PubMed ID: 17724836
    [No Abstract]   [Full Text] [Related]  

  • 12. [Fixed dose of combination of pioglitazone/metformin].
    Ugi S; Maegawa H
    Nihon Rinsho; 2012 May; 70 Suppl 3():627-32. PubMed ID: 22768589
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.
    Teranishi T; Ohara T; Maeda K; Zenibayashi M; Kouyama K; Hirota Y; Kawamitsu H; Fujii M; Sugimura K; Kasuga M
    Metabolism; 2007 Oct; 56(10):1418-24. PubMed ID: 17884455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glitazones in type 2 diabetes: an update.
    Drug Ther Bull; 2008 Apr; 46(4):25-9. PubMed ID: 18403615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
    Basu R; Shah P; Basu A; Norby B; Dicke B; Chandramouli V; Cohen O; Landau BR; Rizza RA
    Diabetes; 2008 Jan; 57(1):24-31. PubMed ID: 17914032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin dispersible tablets: line extension. A welcome formulation of an essential drug.
    Prescrire Int; 2008 Aug; 17(96):138. PubMed ID: 19480093
    [No Abstract]   [Full Text] [Related]  

  • 17. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comment on 'the risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy'.
    Chang Y; Choi NK; Hahn S; Park BJ
    Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1072-3; author reply 1073-4. PubMed ID: 17907252
    [No Abstract]   [Full Text] [Related]  

  • 19. Total and acylated ghrelin levels in type 2 diabetic patients: similar levels observed after treatment with metformin, pioglitazone or diet therapy.
    Kiyici S; Ersoy C; Oz Gul O; Sarandol E; Demirci M; Tuncel E; Sigirli D; Erturk E; Imamoglu S
    Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):386-90. PubMed ID: 19629933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Consulting Prof. Dr. Stephan Matthaei. Quakenbrück diabetes center. Prescription relevant conclusions].
    Matthaei S
    MMW Fortschr Med; 2007 Apr; 149(15):53. PubMed ID: 17668779
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.